9 Pharmaceuticals Stocks to Sell Now

Advertisement

This week, 9 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This is a rough week for Shire PLC Sponsored ADR (SHPG). The company’s rating falls to D from the previous week’s C. Shire PLC Sponsored ADR a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of SHPG stock.

Mallinckrodt Plc’s (MNK) rating weakens this week, dropping to a D versus last week’s C. For more information, get Portfolio Grader’s complete analysis of MNK stock.

This week, ANI Pharmaceuticals Inc (ANIP) drops from a C to a D rating. ANI Pharmaceuticals Inc develops, manufactures, and markets prescription and over-the-counter pharmaceuticals. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of ANIP stock.

Dipexium Pharmaceuticals, Inc. (DPRX) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of DPRX stock.

Marinus Pharmaceuticals Inc (MRNS) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRNS stock.

Slipping from a C to a D rating, Cumberland Pharmaceuticals Inc. (CPIX) takes a hit this week. Cumberland Pharmaceuticals Inc. engages in the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets primarily in the United States. The company also gets F’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CPIX stock.

Imprimis Pharmaceuticals, Inc. (IMMY) earns a D this week, moving down from last week’s grade of C. Imprimis Pharmaceuticals, Inc. is a pharmaceutical company that focuses on the development and commercialization of non-invasive topically delivered medications. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMMY stock.

Evoke Pharma, Inc. (EVOK) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EVOK stock.

Apricus Biosciences, Inc. (APRI) slips from a C to a D this week. Apricus Biosciences, Inc. engages in the research and development of pharmaceutical drugs and drug candidates based on its proprietary NexACT drug delivery technology. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of APRI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/02/9-pharmaceuticals-stocks-to-sell-now/.

©2024 InvestorPlace Media, LLC